Table 2. Clinical features with continuous measurements for patients who were exposed to and patients who were not exposed to LY-CoV555 treatment, along with their respective mean values and p-values.
| Continuous Variables | Mean in the Exposed Group | Mean in the Unexposed Group | P-value |
| Time to resolution of fever (Days) | 1.98 (0.07) | 3.9 (0.13) | <0.0001 |
| Time to resolution of shortness of breath (Days) | 2.58 (0.07) | 3.91 (0.13) | <0.0001 |
| High lactate dehydrogenase (LDH) | 578.33 (17.02) | 693.09 (29.97) | 0.0011 |
| Pulse oximetry (POX) after Rx | 95.51 (0.27) | 92.98 (0.76) | 0.0023 |
| Age | 81.42 (0.68) | 84.42 (0.89) | 0.0084 |
| High D-dimer | 3.41 (0.3) | 4.1 (0.43) | 0.1933 |
| High creatinine | 1.65 (0.04) | 1.75 (0.06) | 0.2068 |
| High troponin | 0.62 (0.11) | 0.73 (0.19) | 0.5861 |
| High ferritin | 516.26 (19.57) | 503.5 (25.11) | 0.6891 |
| High regular C-reactive protein (CRP) | 9.22 (0.61) | 9.05 (0.85) | 0.8693 |
| Pulse oximetry (POX) before Rx | 95.12 (0.17) | 95.09 (0.26) | 0.9338 |
| High blood urea nitrogen (BUN) | 35.68 (1.01) | 35.74 (1.44) | 0.9729 |